DOVETAIL PARTNERS WITH TILLOTTS AG TO MAP MANAGEMENT OF C DIFFICILE INFECTION IN EUROPE
Specialist stakeholder engagement consultancy Dovetail, based in London, UK, have announced a new partnership with Tillotts Pharma AG to support the launch of Tillotts’ recent acquisition DIFICLIR™ in the EU.
DIFICLIR™ (fidaxomicin) is a narrow-spectrum macrocyclic anti-bacterial agent available as film-coated tablets and granules, indicated as a treatment for Clostridioides difficile infection (CDI). CDI is estimated to affect more than 100,000 people in Europe every year. Symptoms include diarrhoea, stomach pain and fever, and mortality can be as high as 25% in frail, elderly people in hospitals.
Tillotts Pharma AG recently acquired the rights to DIFICLIR™ from Astellas Pharma Europe Ltd for Europe, Middle East, Africa and selected CIS. Dovetail’s support will help the company to gain insights into the strategic context for, and operational practicalities of CDI management in Italy and Greece.
Managing Director of Dovetail, Claire Munro said, “Dovetail’s purpose is to help industry and clinicians collaborate more effectively, so they can accelerate better outcomes for patients. CDI is a serious, life threatening condition affecting vulnerable populations, and DIFICLIR™ offers significant benefits. We’re delighted to be appointed by Tillotts international headquarters to play a role in helping them continue to establish this important treatment option. It’s a great fit for us, building on our extensive experience and track record of delivering strategic stakeholder engagement initiatives for our clients, ultimately helping them improve patient outcomes.”
For more information please contact:
Claire Munro, Managing Director
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common purpose and build lasting value for all.